AmuSED: Assessment of the Mu-Drop System for Serum Eye Drops

Sponsor

Sanquin Research & Blood Bank Divisions (Other)

Overall Status

Unknown status

CT.gov ID

NCT03539159

Collaborator

Radboud University Medical Center (Other), Leiden University Medical Center (Other), UMC Utrecht (Other), Maastricht University Medical Center (Other), Amsterdam UMC, location AMC (Other), The Rotterdam Eye Hospital (Other)

Enrollment

Locations

Arms

13.9

Anticipated Duration (Months)

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Rationale: Serum eye drops (SEDs) are used to treat patients with severe signs and symptoms of dry eyes and other corneal defects. Serum is used in severe ophthalmic cases where conventional treatment and/or eye drops (artificial tears) have insufficient effect. The use of SEDs in dry eye patients usually has a rapid effect. Most patients claim the effect to be instantaneous, and most symptoms improve within 48-72 hours.

There is evidence suggesting that substances in serum may help in the healing of epithelial defects, such as epidermal growth factor, fibroblast growth factor, fibronectin, and/or vitamin A. However, the precise serum factor responsible for alleviating the patient's complaints is currently not known.

SEDs are considered as a blood product under EU blood legislation (Directive 2002/98/EC), as well as in New Zealand and Australia. Commonly, autologous SEDs are used, but they are replaced more and more by allogeneic SEDs prepared from donor serum. Allogeneic SEDs are derived from healthy voluntary, non-remunerated male donors with blood group AB, and have the benefit of blood bank controlled quality. They can be delivered from stock and are therefore quickly available for each patient.

For application of eye drops, generally administration systems with a drop size of 40 to 50 µl are used, further on referred to as conventional sized eye drops. From previous studies done with medicinal eye drops, it has been shown that smaller eye drops, so called micro drops, can be just as effective and sometimes even superior to conventional drops for treatment of eye disease. If micro drops are just as effective or maybe even superior to conventional sized eye drops is currently unknown for the use of SEDs. This study will compare the feasibility and effectiveness of allogeneic serum micro eye drops using the mu-Drop applicator to the conventional sized allogeneic eye drops using the Meise applicator. Both systems have a closed manufacturing system.

Objective: The main objective is to determine whether the administration of allogeneic serum micro eye drops is non-inferior in terms of effectiveness and safety as compared to the conventional sized drops.

Main study parameters/endpoints: The primary endpoint is the improvement in OSDI score by using SEDs (OSDI score after treatment minus OSDI score before treatment), independent of the drop size, showing non-inferiority for the use of micro drops as compared to conventional sized drops.

Condition or Disease	Intervention/Treatment	Phase
Dry Eye Syndrome	Other: Allogeneic conventional sized serum eye drops Other: Allogeneic micro sized serum eye drops	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

54 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double (Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Allogenic Serum Micro Eye Drops Compared to Conventional Sized Eye Drops: A Prospective Randomized Non-inferiority, Investigator Masked, Cross-over Multicenter Clinical Study

Actual Study Start Date :

Dec 6, 2018

Anticipated Primary Completion Date :

Dec 1, 2019

Anticipated Study Completion Date :

Feb 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Allogeneic conventional sized serum eye drops	Other: Allogeneic conventional sized serum eye drops allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month Other: Allogeneic micro sized serum eye drops Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
Experimental: Allogeneic micro sized serum eye drops	Other: Allogeneic conventional sized serum eye drops allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month Other: Allogeneic micro sized serum eye drops Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month

Arm

Intervention/Treatment

Experimental: Allogeneic conventional sized serum eye drops

Other: Allogeneic conventional sized serum eye drops

allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month

Other: Allogeneic micro sized serum eye drops

Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month

Experimental: Allogeneic micro sized serum eye drops

Other: Allogeneic conventional sized serum eye drops

Other: Allogeneic micro sized serum eye drops

Outcome Measures

Primary Outcome Measures

Ocular Surface Disease Index (OSDI index) [One month after starting the intervention]
The primary endpoint is the improvement in OSDI score by using SEDs (OSDI score after treatment minus OSDI score before treatment), independent of the drop size, showing non-inferiority for the use of micro drops as compared to conventional sized drops. The OSDI score falls between 0 and 100, ranging from normal, mild, moderate to severe dry eyes.

Secondary Outcome Measures

Schirmer's test [One month after starting the intervention]
Tear production in mm
Tear break up time [One month after starting the intervention]
number of seconds the dry spot appears in the ter film
Corneal punctates [One month after starting the intervention]
Percentage of affected surface after staining of the cornea

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects with severe signs and symptoms of dry eyes.
Age 16 years or older.
Punctate staining of the cornea.
Expected to benefit from SEDs.
Not previously treated with SEDs.

Exclusion Criteria:

Actively or previously treated for Herpes Simplex Virus (HSV) keratitis.
Corneal lesions, more than punctate.
Untreated Meibomian gland disease.
Pregnant or lactating or intending to become pregnant in the next 3 months
Unable or unwilling to give informed consent.
Active (systemic) microbial infection.
The use of all types of contact lenses.
Discontinuous use of medication that affects the dry eye sensation is not allowed (e.g. discontinuous use of local corticosteroids). Continuous use of co-medication, like lubricants, anti-glaucoma eye drops or other drops, that have to be used on a daily basis are allowed, and are expected to be used throughout the study period in both eyes (continuous use of the same medication is allowed if used at least one month prior to start of the study).

Contacts and Locations

Locations

	Site	City	Country
1	Academic Medical Center Amsterdam	Amsterdam-Zuidoost	Netherlands
2	Leiden University Medical Center	Leiden	Netherlands
3	Maastricht University Medical Center	Maastricht	Netherlands
4	Radboudumc	Nijmegen	Netherlands
5	The Rotterdam Eye Hospital	Rotterdam	Netherlands
6	UMC Utrecht	Utrecht	Netherlands